We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carotenoid Supplementation and Normal Ocular Health

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02147171
First Posted: May 26, 2014
Last Update Posted: May 26, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Laura Patryas, University of Manchester
  Purpose
Normal ageing affects vision as a result of preretinal and retinal changes. Photoreceptors, the light sensitive cells in the retina, degenerate and the rods (responsible for night vision) are most susceptible to damage with increasing age. Rod loss leads to poor vision in the dark which increases the risk of accidents amongst the elderly. Macular pigment (located in the photoreceptors)is thought to protect the retina and reduce the risk of age related changes. Dark adaptation, mediated by the rods, slows down with age, and is also reduced in AMD (age-related macular degeneration). Recent evidence suggests that lutein (the main component of macular pigment) supplementation improves the dark adaptation deficit in AMD subjects. Research into the effects of lutein in a normal human has not been previously conducted. Since the older population is increasing, our aim is to firstly establish the extent of night vision loss (using dark adaptometry) and secondly to examine the possibility of slowing down or reversing this loss through lutein supplementation.

Condition Intervention Phase
Retinal Ageing Dietary Supplement: VisionAce Dietary Supplement: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Bioavailability of Retinal Carotenoids in the Older Human Eye and Their Effects on Photoreceptor Performance

Further study details as provided by Laura Patryas, University of Manchester:

Primary Outcome Measures:
  • Changes in macular pigment optical density [ Time Frame: 12 months ]
  • Changes in serum lutein [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Changes in visual performance [ Time Frame: 12 months ]

    The following parameters of visual function will be assessed:

    Visual acuity Contrast Sensitivity Resolution limit Dark adaptation



Enrollment: 88
Study Start Date: November 2011
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active lutein group
44 participants taking VisionAce daily for a period of 1 year
Dietary Supplement: VisionAce
Placebo Comparator: Placebo group
44 participants taking placebo daily for a period of 1 year
Dietary Supplement: Placebo

Detailed Description:

It is believed that the macular pigment protects the retina against photooxidative damage which can lead to agerelated macular degeneration (AMD). It is also hypothesized to enhance visual performance in normal human eyes. Much of the research into lutein supplementation has been centered around AMD subjects. AMD can result from agerelated retinal photoreceptor dysfunction which could hypothetically be prevented or slowed down through early supplementation. To our knowledge, the effects of lutein in normal ageing, have not been studied previously.

Macular pigment is composed of lutein and zeaxanthin. These compounds absorb blue light and therefore protect the retinal photoreceptors. They also possess powerful antioxidant properties and therefore help maintain the integrity of the macular region. With increasing age, the visual performance worsens as a result of preretinal and retinal changes such as photoreceptor degeneration. Rods (responsible for night vision) are highly susceptible to degeneration in a normal aging eye and in AMD. Older subjects often complain of reduced vision in the dark which can contribute to increased risk of road traffic accidents and falls. Since the older population is rapidly growing, it is vital to study the mechanics of photoreceptor degeneration and the possible beneficial effects of supplementation with retinal carotenoids, particularly lutein.

The supplement that will be used in this study will be the commercially available Visionace Plus (details attached). The manufacturer of Visionace Plus is Vitabiotics. The placebo will be soya-based, also manufactured by Vitabiotics.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Not on food supplements containing lutein or zeaxanthin
  2. Visual acuity at least 0.4 logMAR units (6/15 Snellen)

4. Body mass index of less than 35 5. No diagnosed ocular disease (e.g. established AMD, cataract, glaucoma) 6. Age between 50 and 90

Exclusion Criteria:

  1. Diabetes
  2. Any diagnosed ocular disease (e.g. AMD, cataract, glaucoma)
  3. Under 50 and over 90 years old
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02147171


Locations
United Kingdom
University of Manchester
Manchester, United Kingdom, M13 9PL
Sponsors and Collaborators
University of Manchester
Investigators
Study Director: Ian Murray University of Manchester
  More Information

Responsible Party: Laura Patryas, Miss, University of Manchester
ClinicalTrials.gov Identifier: NCT02147171     History of Changes
Other Study ID Numbers: BB/F017227/1
First Submitted: April 16, 2014
First Posted: May 26, 2014
Last Update Posted: May 26, 2014
Last Verified: April 2014

Keywords provided by Laura Patryas, University of Manchester:
Retinal ageing, macular pigment, visual function

Additional relevant MeSH terms:
Carotenoids
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs